Evotec Results Presentation Deck

● evotec Strong overall performance Fully in line with strategy - investments for long-term growth Financials H1 2021 & FY 2021 Guidance Group revenues increase by 17% to € 271.3 m (H1 2020: € 231.0 m). Organic growth at record level of 27% Adjusted Group EBITDA¹) of € 36.2 m (H1 2020: € 47.3 m) mainly affected by planned capacity build-up ahead of imminent production start of J.PODⓇ 1 US. Like-for-like growth 13% • Increase of expenses for unpartnered R&D by 29% to € 27.8 m (H1 2020: € 21.6 m) PAGE 5 Despite high investments in new J.PODⓇ 1 US and other capacity expansions, Net debt leverage ratio remains at even negative level -1.0 x adjusted EBITDA excl. IFRS 16 Confirmation of 2021 outlook & Action Plan 2025 ambitions Group revenues € 550 - 570 m (2020: € 500.9 m) Adjusted Group EBITDA € 105 -120 m (2020: € 106.6 m) Unpartnered R&D € 50 - 60 m (2020: € 46.4 m) • Action Plan 2025 targets confirmed: Revenues > € 1,000 m, adjusted EBITDA > € 300 m, unpartnered R&D > € 100 m ¹) Before contingent considerations, income from bargain purchase & excluding impairments on goodwill, other intangible & tangible assets as well as the total non-operating result

View entire presentation